Filing Details

Accession Number:
0000950170-25-010594
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-01-29 17:25:01
Reporting Period:
2025-01-27
Accepted Time:
2025-01-29 17:25:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1936258 Newamsterdam Pharma Co N.v. NAMS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1760303 Ian Mayur Somaiya C/O Newamsterdam Pharma Company N.v.
Gooimeer 2-35
Naarden P7 1411 DC
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2025-01-27 46,983 $9.26 84,983 No 4 M Direct
Ordinary Shares Disposition 2025-01-27 33,679 $0.00 51,304 No 4 S Direct
Ordinary Shares Disposition 2025-01-27 13,304 $0.00 38,000 No 4 S Direct
Ordinary Shares Acquisiton 2025-01-28 14,900 $9.26 52,900 No 4 M Direct
Ordinary Shares Disposition 2025-01-28 11,495 $0.00 41,405 No 4 S Direct
Ordinary Shares Disposition 2025-01-28 3,405 $0.00 38,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Option (Right to Buy) Disposition 2025-01-27 46,983 $0.00 46,983 $9.26
Ordinary Shares Option (Right to Buy) Disposition 2025-01-28 14,900 $0.00 14,900 $9.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
777,714 2033-11-01 No 4 M Direct
762,814 2033-11-01 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  2. These shares were sold in multiple transactions at prices ranging from $22.38 per share to $23.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. These shares were sold in multiple transactions at prices ranging from $23.38 per share to $23.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. These shares were sold in multiple transactions at prices ranging from $20.93 per share to $21.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  5. These shares were sold in multiple transactions at prices ranging from $21.93 per share to $22.41 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  6. The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.